The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML
Juan Miguel Bergua-Burgues, MD, Hospital San Pedro de Alcantara, Cáceres, Spain, comments on VEN-A-QUI (NCT04687761), a Phase I/II trial assessing the combination of low-dose cytarabine or azacitidine plus venetoclax and quizartinib in elderly patients with newly diagnosed acute myeloid leukemia (AML). Dr Bergua-Burgues explains that the study will include subsets of patients who are FLT3-ITD+, as well as patients with secondary AML (sAML). In addition, Dr Bergua-Burgues notes that whilst the study reported promising efficacy results, it is important to amend the protocol to minimize toxicity. Moving forward, Dr Bergua-Burgues specifies the patient population included in this study. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
